Tags

Type your tag names separated by a space and hit enter

In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Diagn Microbiol Infect Dis. 2007 May; 58(1):27-32.DM

Abstract

Garenoxacin is a novel des-F(6)-quinolone with a chemical structure that lacks the C6 position fluorine and has a unique difluoromethoxy substitution at position C8. This study evaluated the in vitro activity of garenoxacin tested against a large collection of Enterobacteriaceae collected worldwide. The bacterial isolates were consecutively collected from more than 70 medical centers from bloodstream, respiratory, urinary tract, and skin and soft tissue infections. The isolates were tested against garenoxacin, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and many other oral and parenteral antimicrobial agents. All isolates were susceptibility tested by broth microdilution methods according to the Clinical and Laboratory Standards Institute (CLSI) guidelines and interpretative criteria. A garenoxacin-susceptible breakpoint of < or =2 microg/mL was applied for comparison purposes only. The fluoroquinolones were the most active oral compounds with overall susceptibility rates of 87.5% to 90.0%. Garenoxacin showed in vitro activity comparable with that of ciprofloxacin and the other fluoroquinolones against Escherichia coli (MIC(50), < or =0.03 microg/mL; 87.3% susceptible), Klebsiella spp. (MIC(50), 0.12 microg/mL; 90.4-94.5% susceptible), Enterobacter spp. (MIC(50), 0.12 microg/mL; 85.6-86.5% susceptible), Salmonella spp. (MIC(50), 0.06 microg/mL; 99.7% susceptible), and Shigella spp. (MIC(50), < or =0.03 microg/mL; 99.9% susceptible), which accounted for 87.0% of the Enterobacteriaceae strains tested. Garenoxacin was highly active against ciprofloxacin-susceptible strains (98.1% susceptibility), whereas ciprofloxacin-resistant strains were generally resistant to all other fluoroquinolones and also showed high rates of resistance to other orally administered antimicrobials. In conclusion, garenoxacin in vitro activity was similar to that of currently marketed fluoroquinolones and superior to other orally administered antimicrobial agents (cephalosporins, amoxicillin/clavulanate, and trimethoprim/sulfamethoxazole) when tested against more than 45,000 globally collected Enterobacteriaceae.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA. helio-sader@jmilabs.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17383140

Citation

Sader, Helio S., et al. "In Vitro Activity of Garenoxacin Tested Against a Worldwide Collection of Ciprofloxacin-susceptible and Ciprofloxacin-resistant Enterobacteriaceae Strains (1999-2004)." Diagnostic Microbiology and Infectious Disease, vol. 58, no. 1, 2007, pp. 27-32.
Sader HS, Fritsche TR, Jones RN. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). Diagn Microbiol Infect Dis. 2007;58(1):27-32.
Sader, H. S., Fritsche, T. R., & Jones, R. N. (2007). In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). Diagnostic Microbiology and Infectious Disease, 58(1), 27-32.
Sader HS, Fritsche TR, Jones RN. In Vitro Activity of Garenoxacin Tested Against a Worldwide Collection of Ciprofloxacin-susceptible and Ciprofloxacin-resistant Enterobacteriaceae Strains (1999-2004). Diagn Microbiol Infect Dis. 2007;58(1):27-32. PubMed PMID: 17383140.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). AU - Sader,Helio S, AU - Fritsche,Thomas R, AU - Jones,Ronald N, Y1 - 2007/03/23/ PY - 2006/12/07/received PY - 2006/12/07/accepted PY - 2007/3/27/pubmed PY - 2007/6/30/medline PY - 2007/3/27/entrez SP - 27 EP - 32 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 58 IS - 1 N2 - Garenoxacin is a novel des-F(6)-quinolone with a chemical structure that lacks the C6 position fluorine and has a unique difluoromethoxy substitution at position C8. This study evaluated the in vitro activity of garenoxacin tested against a large collection of Enterobacteriaceae collected worldwide. The bacterial isolates were consecutively collected from more than 70 medical centers from bloodstream, respiratory, urinary tract, and skin and soft tissue infections. The isolates were tested against garenoxacin, ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and many other oral and parenteral antimicrobial agents. All isolates were susceptibility tested by broth microdilution methods according to the Clinical and Laboratory Standards Institute (CLSI) guidelines and interpretative criteria. A garenoxacin-susceptible breakpoint of < or =2 microg/mL was applied for comparison purposes only. The fluoroquinolones were the most active oral compounds with overall susceptibility rates of 87.5% to 90.0%. Garenoxacin showed in vitro activity comparable with that of ciprofloxacin and the other fluoroquinolones against Escherichia coli (MIC(50), < or =0.03 microg/mL; 87.3% susceptible), Klebsiella spp. (MIC(50), 0.12 microg/mL; 90.4-94.5% susceptible), Enterobacter spp. (MIC(50), 0.12 microg/mL; 85.6-86.5% susceptible), Salmonella spp. (MIC(50), 0.06 microg/mL; 99.7% susceptible), and Shigella spp. (MIC(50), < or =0.03 microg/mL; 99.9% susceptible), which accounted for 87.0% of the Enterobacteriaceae strains tested. Garenoxacin was highly active against ciprofloxacin-susceptible strains (98.1% susceptibility), whereas ciprofloxacin-resistant strains were generally resistant to all other fluoroquinolones and also showed high rates of resistance to other orally administered antimicrobials. In conclusion, garenoxacin in vitro activity was similar to that of currently marketed fluoroquinolones and superior to other orally administered antimicrobial agents (cephalosporins, amoxicillin/clavulanate, and trimethoprim/sulfamethoxazole) when tested against more than 45,000 globally collected Enterobacteriaceae. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17383140/In_vitro_activity_of_garenoxacin_tested_against_a_worldwide_collection_of_ciprofloxacin_susceptible_and_ciprofloxacin_resistant_Enterobacteriaceae_strains__1999_2004__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(06)00498-6 DB - PRIME DP - Unbound Medicine ER -